DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Hehlmann R, Lauseker M, Saußele S. et al.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Leukemia 2017;
31 (11) 2398-2406
We do not assume any responsibility for the contents of the web pages of other providers.